• Clinical Development
  • Translational Medicine Research Center
  • Pipeline
  • Synergized Oncology Portfolio Capturing Value in the Era of Combo Therapy

    Pls slide for the whole picture.

    • Ivosidenib (CS3010)
      A First-In-Class, orally available, selective and potent IDH1m inhibitor
    • >>> Asset overview :

      Approved by the US FDA in July 2018 for the treatment of R/R IDH1m AML

      Licensed from Agios in 2018

    • Avapritinib (CS3007)
      A First-In-Class, orally available, potent and highly selective PDGFRα and KIT inhibitor candidate
    • >>> Asset overview :

      US FDA designations: Breakthrough Therapy, Fast Track, Orphan Drug

      Licensed in from Blueprint in 2018

    • CS1001
      A fully human, full-length IgG4 anti-PD-L1 mAb
    • >>> Asset overview :

      In phase 1a study, CS1001 was well tolerated and demonstrated promising anti-tumor activities and PRs in several tumor types (data presented in ESMO 2018)

    • CS3008
      A potentially first-in-class, orally available, potent, selective and irreversible inhibitor of FGFR4
    • >>> Asset overview :

      US FDA designations: Orphan Drug

      Licensed in from Blueprint in 2018

    • CS3009
      An orally available, potent and highly selective RET inhibitor
    • >>> Asset overview :

      Licensed in from Blueprint in 2018

    • CS1002
      A fully-human monoclonal antibody against CTLA-4
    • >>> Asset overview :

      A biosimilar of ipilimumab (Yervoy)

    • CS1003
      A humanized IgG4 monoclonal antibody against programmed death receptor 1 (PD-1)
    • >>> Asset overview :

      A humanized IgG4 anti-PD-1 mAb that is cross-reactive to both human and mouse PD-1

    • CS3006
      A highly selective MEK inhibitor
    • >>> Asset overview :

      An orally available, small molecule inhibitor of mitogen-activated extracellular signal regulated kinases 1 and 2 (MEK1 and MKE2)

    • CS3002
      A small molecule inhibitor targeting on cyclin-dependent kinase 4 and 6 (CDK4/6)
    • >>> Asset overview :

      CDK4/6 inhibition prevents G1-S phase transition adn induces cell-cycle arrest of tumor cells and small molecule inhibitors of CDK4/6 have become standard treatment for certain solid tumors

    • CS3003
      A small molecule inhibitor selectively targeting on histone deacetylases 6 (HDAC6)
    • >>> Asset overview :

      Selective inhibition of HDAC6 may lead to better efficacy in multiple myeloma with an improved safety profile